Literature DB >> 24937002

Clozapine-induced concordant agranulocytosis in monozygotic twins.

J Horáček J Libiger C Höschl K Borzova I Hendrychová.   

Abstract

Two monozygotic twin sisters were admitted to a psychiatric hospital and diagnosed as having first-episode schizophrenia. Clozapine treatment led to the complete remission of psychotic symptoms within a short time. In both twins the low leukocyte count was detected after 9 weeks of clozapine. Serological typing of the HLA system was performed and an identical pattern was detected in both twins: HLA-A: 28, 26; HLA-B: 49, 63; DR: 2 (vs 16), 12, 52; DQ:1. It is the first report of concordant manifestation of clozapine-induced agranulocytosis in monozygotic twins. Our case report of twins afflicted synchronously with schizophrenia and later with agranulocytosis after clozapine is of interest because it suggests that genetic factors may participate not only in timing of onset of schizophrenia, but also in the emergence and timing of agranulocytosis in response to clozapine treatment. ( Int J Psych Clin Pract 2001; 5:71-73).

Entities:  

Keywords:  Clozapine Monozygotic Twins Timing Agranulocytosis Genetic Factors

Year:  2001        PMID: 24937002     DOI: 10.1080/136515001300225231

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  12 in total

Review 1.  Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.

Authors:  Shareefa Dalvie; Nastassja Koen; Nathaniel McGregor; Kevin O'Connell; Louise Warnich; Raj Ramesar; Caroline M Nievergelt; Dan J Stein
Journal:  OMICS       Date:  2016-09-16

Review 2.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

3.  Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.

Authors:  K van der Weide; H Loovers; K Pondman; J Bogers; T van der Straaten; E Langemeijer; D Cohen; J Commandeur; J van der Weide
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 4.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

5.  Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.

Authors:  Danielle L Taylor; Arun K Tiwari; Jeffrey A Lieberman; Steven G Potkin; Herbert Y Meltzer; Joanne Knight; Gary Remington; Daniel J Müller; James L Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-10-12

6.  Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Authors:  Robert L Smith; Tore Haslemo; Ole A Andreassen; Erik Eliasson; Marja-Liisa Dahl; Olav Spigset; Espen Molden
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

Review 7.  Genetic predictors of therapeutic response to clozapine: current status of research.

Authors:  Dalu Mancama; Maria J Arranz; Robert W Kerwin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  More than 25 years of genetic studies of clozapine-induced agranulocytosis.

Authors:  S A J de With; S L Pulit; W G Staal; R S Kahn; R A Ophoff
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

Review 9.  Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Authors:  Shusuke Numata; Hidehiro Umehara; Tetsuro Ohmori; Ryota Hashimoto
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

10.  Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.

Authors:  C Okhuijsen-Pfeifer; E A H Huijsman; A Hasan; I E C Sommer; S Leucht; R S Kahn; J J Luykx
Journal:  Acta Psychiatr Scand       Date:  2018-09-14       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.